The last time InspireMD reported earnings, the story fell apart in real time. Three straight quarters of accelerating US launch momentum for its C-Guard Prime 135 carotid stent culminated in a voluntary recall, a withdrawn full-year revenue guide of $13 to $15 million, and a tone shift from talk of 'dominating this space' to language about a 'temporary and correctable' setback. This upcoming report is the first full quarter investors get to see just how deep that setback cuts, and whether the underlying demand story management insists is still intact actually shows up in the numbers.

Consensus calls for revenue of $1.7 million and an EPS loss of $0.20. That revenue figure represents a 7.2% year-over-year decline, a jarring reversal from the 122% growth InspireMD posted just one quarter earlier when total revenue hit $3.4 million. The comparison matters because it isolates exactly what the market expects to happen once US commercial activity goes to zero. With no US sales contribution until an anticipated Q3 2026 re-entry using the legacy delivery system, this quarter is essentially a clean read on international demand alone. Given that international revenue ran $2.2 million in the prior quarter, up 48% year over year on real volume rather than just currency tailwinds, the $1.7 million consensus estimate implies the Street expects some sequential softening even in the business segment that wasn't directly hit by the recall. That is worth watching closely, because if international sales hold up or grow, it reinforces management's claim that the implant itself performs well and that the Prime 135 issue was a delivery-system problem, not a demand problem. If international sales also disappoint, the narrative gets harder to defend.

The EPS comparison offers a more modest signal. A loss of $0.20 versus a year-ago loss of $0.26 represents improvement, but the prior quarter's loss was $0.16, so sequentially the loss is expected to widen. That aligns with management's own disclosure that Q2 would absorb roughly $700,000 in customer return reserves and about $650,000 in inventory impairment and remediation costs tied to the recall. Investors should treat gross margin as a critical data point this quarter. GAAP gross margin cratered to 20.2% last quarter from 37.5% the quarter before, partly due to a one-time inventory impairment. Whether margin stabilizes near that adjusted 34% level or deteriorates further because of the newly flagged return reserves will say a lot about how contained the financial damage really is.

Sentiment has ticked up modestly, moving from -0.022 ahead of the last report to +0.044 now, suggesting expectations are neither despairing nor euphoric heading into this print. That is a reasonable posture given the stock's performance since the last report. NSPR has fallen 17.6% while the S&P 500 gained 7.8%, a relative underperformance of over 25 percentage points. The stock now trades at $0.84, well below its 200-day moving average of $1.42, and sits closer to the low end of its post-earnings range of $0.63 to $1.29 than the high. That range itself is dramatically compressed compared with the prior quarter's $1.04 to $1.98 band, reflecting how much air came out of the stock after the recall news.

The central question this report needs to answer is not whether InspireMD can beat a modest consensus estimate. It is whether the company can demonstrate that its core demand engine, particularly international volume and the pipeline of centers still queued up for eventual US reactivation, remains intact while it navigates a multi-quarter US commercial blackout. Confirmation of stable or growing international revenue, contained cash burn from the $41.6 million balance reported last quarter, and no new surprises on the legacy delivery system's regulatory timeline would all support the recovery thesis management is asking investors to believe in. Any further slippage on those fronts would suggest the damage extends beyond a single product recall.